LOW-VOLUME · HOSP-MID

ertugliflozin Side Effects

ertugliflozin (also sold as Steglatro) is a LOW-VOLUME FAERS extract #488 of 524 by FAERS report count. Still opens on HOSP-MID: 28.0% mention hospitalization (290 reports).

Data updated 2026-05-15

1,037
FAERS reports

Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.

ertugliflozin: 28.0% mention hospitalization (290 reports). Death stamp DEATH-MARKED; volume band LOW-VOLUME #488 of 524 by FAERS report count.

Thinner FAERS extract for ertugliflozin (Steglatro) (1,037 reports #488 of 524 by FAERS report count). 28.0% mention hospitalization (290 reports). Sparse books still carry named reaction rows when present; not medical advice.

Counts from the openFDA FAERS extract (2013–2025). Stamps SIGNAL · DEATH-MARKED · HOSP-MID · SEX-BALANCED.

NAUSEA leads 86 of 1,037 reports

NAUSEA
86
URINARY TRACT INFECTION
62
VOMITING
59
FUNGAL INFECTION
58
DIABETIC KETOACIDOSIS
51
BLOOD GLUCOSE INCREASED
46
DIZZINESS
46
DIARRHOEA
43
PRODUCT DOSE OMISSION
29
DECREASED APPETITE
25
DIABETES MELLITUS INADEQUATE CONTROL
25
RASH
25
FATIGUE
23
ASTHENIA
21
INABILITY TO AFFORD MEDICATION
21
PALPITATIONS
21

Who reports · age peak 45-64 (SEX-BALANCED)

Sex coding · SEX-BALANCED

Female 537 (55%)
Male 444 (45%)
Unknown 4

Age peak 45-64 (271 reports)

0-17 7 (1%)
18-44 111 (20%)
45-64 271 (48%)
65-74 121 (22%)
75+ 51 (9%)

FAERS filings rising toward 2025

13
17
18
19
20
21
22
23
24
25

Reactions in Death Reports

Death appears on 12 reports (1.2% - MARKED). Reactions below co-occur in those rows only.

Reaction Reports
DEATH 4
OEDEMA PERIPHERAL 3
SEPSIS 3
BLOOD ALBUMIN DECREASED 2
BLOOD ALKALINE PHOSPHATASE INCREASED 2
BLOOD CALCIUM DECREASED 2
BLOOD CREATININE DECREASED 2
C-REACTIVE PROTEIN ABNORMAL 2
CARDIAC ARREST 2
CHOLELITHIASIS 2
ENTEROCOCCAL INFECTION 2
GAMMA-GLUTAMYLTRANSFERASE INCREASED 2
HEPARIN-INDUCED THROMBOCYTOPENIA 2
HYPERGLYCAEMIA 2
ORGAN FAILURE 2
PANCREATIC DUCT OBSTRUCTION 2
PANCREATITIS NECROTISING 2
PROTEIN TOTAL DECREASED 2
PULMONARY EMBOLISM 2
WOUND NECROSIS 2

Reactions in Hospitalization Reports

Hospitalization mid-share (290, 28.0%). Co-reported reactions:

Reaction Reports
DIABETIC KETOACIDOSIS 45
VOMITING 25
NAUSEA 24
URINARY TRACT INFECTION 20
DECREASED APPETITE 18
DIARRHOEA 14
DIZZINESS 14
FOURNIER^S GANGRENE 14
BRASH SYNDROME 13
EUGLYCAEMIC DIABETIC KETOACIDOSIS 13
PNEUMONIA 12
ABDOMINAL PAIN 10
ACUTE KIDNEY INJURY 10
DIABETES MELLITUS 10
ASTHENIA 9
IMPAIRED GASTRIC EMPTYING 9
KETOACIDOSIS 9
CONSTIPATION 8
DIABETES MELLITUS INADEQUATE CONTROL 8
How to read ertugliflozin FAERS figures (SIGNAL · DEATH-MARKED · HOSP-MID)

FAERS holds 1,037 voluntary reports linked to ertugliflozin (Steglatro), 2013-2025. Death is listed on 12 (1.2%). Hospitalization appears on 290 (28.0%). Top co-reported indication: Type 2 Diabetes Mellitus.

Sparse extract - named reactions and SEX-BALANCED skew still differ by drug; not a complete safety profile.

Read with ertugliflozin

Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-MID stamps.